Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Infectious Diseases Japan

Vical/Astellas's TransVax first therapeutic CMV vaccine to Phase III

This article was originally published in Scrip

  • News

Executive Summary

Vical and partner Astellas have become the first firms to take an investigational therapeutic vaccine for cytomegalovirus (CMV) into a Phase III clinical study, moving their candidate TransVax (ASP0113) into a pivotal multinational program in hematopoietic stem cell transplant (HSCT) recipients.

You may also be interested in...



Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili

Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.

Asahi Paying $1.3bn For One-Product Veloxis

Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.

Ebb TIDES As Takeda’s Dengue Contender Weaker At 18 Months

Takeda's TAK-003 generally positive in new 18-month analysis, but efficacy falls versus 12 months and lowest effectiveness again seen against serotype 3.
Table

View full table

Topics

Related Companies

Tags:
Infectious Diseases Japan
UsernamePublicRestriction

Register

SC021863

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By